CY1119768T1 - Συνθεση περιλαμβανουσα νικοτινη και οπιπραμολη και χρηση αυτης - Google Patents

Συνθεση περιλαμβανουσα νικοτινη και οπιπραμολη και χρηση αυτης

Info

Publication number
CY1119768T1
CY1119768T1 CY20171101027T CY171101027T CY1119768T1 CY 1119768 T1 CY1119768 T1 CY 1119768T1 CY 20171101027 T CY20171101027 T CY 20171101027T CY 171101027 T CY171101027 T CY 171101027T CY 1119768 T1 CY1119768 T1 CY 1119768T1
Authority
CY
Cyprus
Prior art keywords
operamol
nicotinin
inclusive
composition
nicotinic
Prior art date
Application number
CY20171101027T
Other languages
Greek (el)
English (en)
Inventor
Eliahu Heldman
Original Assignee
Neuroderm Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=40380297&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CY1119768(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Neuroderm Ltd filed Critical Neuroderm Ltd
Publication of CY1119768T1 publication Critical patent/CY1119768T1/el

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/465—Nicotine; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/136—Amines having aromatic rings, e.g. ketamine, nortriptyline having the amino group directly attached to the aromatic ring, e.g. benzeneamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/167—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/27—Esters, e.g. nitroglycerine, selenocyanates of carbamic or thiocarbamic acids, meprobamate, carbachol, neostigmine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4406—Non condensed pyridines; Hydrogenated derivatives thereof only substituted in position 3, e.g. zimeldine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32—Alcohol-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/34—Tobacco-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/36—Opioid-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Psychiatry (AREA)
  • Addiction (AREA)
  • Pain & Pain Management (AREA)
  • Emergency Medicine (AREA)
  • Psychology (AREA)
  • Dermatology (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
CY20171101027T 2007-11-26 2017-10-04 Συνθεση περιλαμβανουσα νικοτινη και οπιπραμολη και χρηση αυτης CY1119768T1 (el)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US99016107P 2007-11-26 2007-11-26
PCT/IL2008/001546 WO2009069126A1 (en) 2007-11-26 2008-11-26 Compositions comprising nicotinic agonists and methods of using same

Publications (1)

Publication Number Publication Date
CY1119768T1 true CY1119768T1 (el) 2018-06-27

Family

ID=40380297

Family Applications (1)

Application Number Title Priority Date Filing Date
CY20171101027T CY1119768T1 (el) 2007-11-26 2017-10-04 Συνθεση περιλαμβανουσα νικοτινη και οπιπραμολη και χρηση αυτης

Country Status (21)

Country Link
US (5) US8273731B2 (https=)
EP (1) EP2224917B1 (https=)
JP (1) JP5456687B2 (https=)
KR (1) KR101613742B1 (https=)
CN (1) CN101925352B (https=)
AR (1) AR069752A1 (https=)
AU (1) AU2008331102B2 (https=)
BR (1) BRPI0819911A2 (https=)
CA (1) CA2744736C (https=)
CL (1) CL2008003507A1 (https=)
CY (1) CY1119768T1 (https=)
DK (1) DK2224917T3 (https=)
ES (1) ES2642873T3 (https=)
HR (1) HRP20171476T1 (https=)
HU (1) HUE035105T2 (https=)
LT (1) LT2224917T (https=)
MX (1) MX2010005804A (https=)
PL (1) PL2224917T3 (https=)
PT (1) PT2224917T (https=)
SI (1) SI2224917T1 (https=)
WO (1) WO2009069126A1 (https=)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CL2008003507A1 (es) 2007-11-26 2009-11-27 Neuroderm Ltd Composicion farmaceutica que comprende nicotina y un inhibidor de la desensibilizacion del receptor de acetilcolina nicotinico (nachr) opipramol; kit farmaceutico; dispositivo medico; y uso para tratar una enfermedad o trastorno del sistema nervioso central o periferico.
KR101563554B1 (ko) 2008-08-01 2015-10-27 퀄컴 테크놀로지스, 인크. 잡음 제거를 위한 통합 시간 필터를 구비한 비디오 인코더
US9801865B2 (en) * 2008-09-24 2017-10-31 The United States Of America As Represented By The Department Of Veteran Affairs Materials and methods for diagnosis, prevention and/or treatment of stress disorders and conditions associated with abeta peptide aggregation
US8529914B2 (en) 2010-06-28 2013-09-10 Richard C. Fuisz Bioactive dose having containing a material for modulating pH of a bodily fluid to help or hinder absorption of a bioactive
SMT202100228T1 (it) 2011-04-29 2021-05-07 Moberg Pharma Ab Composizioni farmaceutiche comprendenti un anestetico locale come bupivacaina per somministrazione locale alla bocca o alla gola
JP6566867B2 (ja) * 2012-07-13 2019-08-28 ペイン セラピューティクス インコーポレイテッド 生きている患者でのアルツハイマー病アッセイ
ES2967693T3 (es) 2014-03-13 2024-05-03 Neuroderm Ltd Composiciones del inhibidor de la dopa descarboxilasa
US10258585B2 (en) 2014-03-13 2019-04-16 Neuroderm, Ltd. DOPA decarboxylase inhibitor compositions
WO2015183530A1 (en) * 2014-05-29 2015-12-03 Goodman Jory F Nicotine derivatives and methods of use
AU2015316523A1 (en) * 2014-09-18 2017-05-04 Neuroderm, Ltd. Opipramol patch
SG10202011669PA (en) * 2014-10-20 2020-12-30 Oyster Point Pharma Inc Methods of treating ocular conditions
EP3821735B1 (en) 2014-12-05 2024-11-20 Juul Labs, Inc. Calibrated dose control
CN109310692B (zh) 2016-04-07 2022-01-25 奥伊斯特普安生物制药公司 治疗眼部病状的方法
US10292977B2 (en) * 2016-04-11 2019-05-21 Neurocea, LLC Compositions and methods for treatment related to fall and fall frequency in neurodegenerative diseases
US10639300B2 (en) 2016-04-12 2020-05-05 Arturo Solis Herrera Compositions and methods for treating nasal and paranasal mucosa diseases with nicotinic acetylcholine receptor agonists
KR102874080B1 (ko) 2016-07-07 2025-10-23 하워드 휴즈 메디컬 인스티튜트 변형된 리간드-게이팅 이온 채널 및 사용 방법
WO2018097629A1 (ko) * 2016-11-24 2018-05-31 에스케이케미칼 주식회사 바레니클린 서방성 제제 및 이의 제조 방법
US11260050B2 (en) 2017-02-16 2022-03-01 United States Government As Represented By The Department Of Veterans Affairs Combination of cotinine plus antioxidant for treatment-resistant depression and correction of astrocytes functional deficit induced by depression and other neuropathological
WO2018156883A1 (en) * 2017-02-23 2018-08-30 Board Of Regents, The University Of Texas System Methods of treatment for cancer, sterol homeostasis, and neurological diseases
JP2021502101A (ja) 2017-11-10 2021-01-28 ハワード ヒューズ メディカル インスティチュート 修飾されたリガンド依存性イオンチャネルおよび使用の方法
LU101519B1 (en) * 2019-12-02 2021-06-07 Herrera Arturo Solis (S)-3-[1-MethyIpyrrolidin-2-yl]pyridine, analogues thereof, precursors thereof, or its derivatives, for the use as a pharmaceutical in form of a solid substance and a tablet
US11331293B1 (en) 2020-11-17 2022-05-17 Neuroderm, Ltd. Method for treatment of Parkinson's disease
US11213502B1 (en) 2020-11-17 2022-01-04 Neuroderm, Ltd. Method for treatment of parkinson's disease
US11844754B2 (en) 2020-11-17 2023-12-19 Neuroderm, Ltd. Methods for treatment of Parkinson's disease
US12161612B2 (en) 2023-04-14 2024-12-10 Neuroderm, Ltd. Methods and compositions for reducing symptoms of Parkinson's disease

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5069094A (en) * 1987-09-08 1991-12-03 Birkestrand Orville J Tube end finishing machine
US5656286A (en) * 1988-03-04 1997-08-12 Noven Pharmaceuticals, Inc. Solubility parameter based drug delivery system and method for altering drug saturation concentration
US5668117A (en) 1991-02-22 1997-09-16 Shapiro; Howard K. Methods of treating neurological diseases and etiologically related symptomology using carbonyl trapping agents in combination with previously known medicaments
US5336675A (en) * 1991-05-14 1994-08-09 Ernir Snorrason Method of treating mania in humans
CA2136019A1 (en) * 1992-05-18 1993-11-25 Robert M. Keenan Use of cotinine to alleviate tobacco withdrawal syndrome
JPH09262287A (ja) * 1996-03-28 1997-10-07 Terumo Corp 薬液注入装置
EP1006798A4 (en) * 1996-09-05 2003-03-05 Massachusetts Inst Technology COMPOSITIONS AND METHODS FOR TREATING NEUROLOGICAL DISORDERS AND NEURODEGENERATIVE DISEASES
DE10018834A1 (de) * 2000-04-15 2001-10-25 Lohmann Therapie Syst Lts Transdermale oder transmucosale Darreichungsformen mit einer nicotinhaltigen Wirkstoffkombination zur Raucherentwöhnung
ATE355854T1 (de) * 2000-08-03 2007-03-15 Antares Pharma Ipl Ag Neue zusammensetzung zur transdermalen und/oder transmukosalen wirkstoffanwendung mit geeignetem therapeutischen spiegel
US20070225379A1 (en) * 2001-08-03 2007-09-27 Carrara Dario Norberto R Transdermal delivery of systemically active central nervous system drugs
US6479076B2 (en) * 2001-01-12 2002-11-12 Izhak Blank Nicotine delivery compositions
DE10134038A1 (de) 2001-07-12 2003-02-06 Hf Arzneimittelforsch Gmbh Wirkstoff-Kombination zur medikamentösen Therapie der Nikotinabhängigkeit
US20030119879A1 (en) * 2001-10-15 2003-06-26 Thomas Landh Nicotine and chocolate compositions
US6852741B2 (en) * 2001-12-31 2005-02-08 University Of Florida Compositions and methods for treatment of neurological disorders
US7045534B2 (en) * 2002-02-12 2006-05-16 The Board Of Trustees Of The Leland Stanford Junior University Methods of reducing angiogenesis
US20040156931A1 (en) * 2002-12-18 2004-08-12 Algorx Administration of capsaicinoids
ITMI20030828A1 (it) 2003-04-18 2004-10-19 Farchemia Srl Procedimento per la preparazione dell'opipramolo.
DK1670433T3 (da) * 2003-10-10 2012-03-12 Ferring Bv Transdermal farmaceutisk formulering til mindskelse af hudrester
CA2551946A1 (en) * 2003-12-31 2005-07-21 Actavis Group Hf Immediate, controlled and sustained release formulations of galantamine
US20050234024A1 (en) * 2004-04-14 2005-10-20 Clarke David E Materials and methods for the treatment of ulcerative colitis
WO2005115471A2 (en) 2004-05-27 2005-12-08 Neurocure Ltd. Methods and compositions for treatment of nicotine dependence and dementias
US20060142349A1 (en) * 2004-12-23 2006-06-29 Pfizer Inc Methods of modulating the activities of alpha-7 nicotinic acetylcholine receptor
US20080014252A1 (en) * 2006-07-14 2008-01-17 Delprete Keith Topical compositions with long lasting effect
US8642612B2 (en) 2006-07-18 2014-02-04 Potomac Pharmaceuticals, Inc. Nicotinic desensitizers and methods of selecting, testing, and using them
US20100234349A1 (en) * 2006-09-04 2010-09-16 Olsen Gunnar M Pharmaceutical combinations of a nicotine receptor modulator and a cognitive enhancer
CL2008003507A1 (es) * 2007-11-26 2009-11-27 Neuroderm Ltd Composicion farmaceutica que comprende nicotina y un inhibidor de la desensibilizacion del receptor de acetilcolina nicotinico (nachr) opipramol; kit farmaceutico; dispositivo medico; y uso para tratar una enfermedad o trastorno del sistema nervioso central o periferico.

Also Published As

Publication number Publication date
JP5456687B2 (ja) 2014-04-02
PT2224917T (pt) 2017-10-17
MX2010005804A (es) 2010-11-30
US20170128432A1 (en) 2017-05-11
CN101925352A (zh) 2010-12-22
AU2008331102B2 (en) 2014-04-10
US20130172321A1 (en) 2013-07-04
WO2009069126A1 (en) 2009-06-04
CL2008003507A1 (es) 2009-11-27
CN101925352B (zh) 2016-03-16
PL2224917T3 (pl) 2018-02-28
SI2224917T1 (sl) 2017-12-29
EP2224917B1 (en) 2017-07-05
US20180303818A1 (en) 2018-10-25
ES2642873T3 (es) 2017-11-20
HUE035105T2 (en) 2018-05-02
CA2744736C (en) 2015-06-09
KR101613742B1 (ko) 2016-04-19
DK2224917T3 (en) 2017-10-16
EP2224917A1 (en) 2010-09-08
HRP20171476T1 (hr) 2017-12-15
US8921356B2 (en) 2014-12-30
AU2008331102A1 (en) 2009-06-04
AR069752A1 (es) 2010-02-17
CA2744736A1 (en) 2009-06-04
US20090149446A1 (en) 2009-06-11
KR20100105841A (ko) 2010-09-30
JP2011504490A (ja) 2011-02-10
BRPI0819911A2 (pt) 2017-06-13
US20150306109A1 (en) 2015-10-29
US8273731B2 (en) 2012-09-25
LT2224917T (lt) 2017-12-27

Similar Documents

Publication Publication Date Title
CY1119768T1 (el) Συνθεση περιλαμβανουσα νικοτινη και οπιπραμολη και χρηση αυτης
CY1116779T1 (el) Αμιδο ενωσεις και η χρηση τους ως φαρμακευτικες ουσιες
CY1111123T1 (el) Μεθοδοι χρησης υποδοχεα gpr119 για να πιστοποιουνται ενωσεις χρησιμες για αυξηση οστικης μαζας σε ενα ατομο
TW200730168A (en) Combination of an H3 antagonist/inverse agonist and an appetite suppressant
CY1113212T1 (el) Σπειροκυκλικες ενωσεις ως αναστολεις αφυδρογονασης τυπου 1 11-βητα υδροξυλ στεροειδους
CY1119800T1 (el) Συνδυασμοι υποδοχεα της 5-ητ4 και αναστολεων ακετυλοχολινεστερασης για τη θεραπεια γνωστικων διαταραχων
DE602007010781D1 (de) N- (phenylmethyl) -2- (1h-pyrazol-4-yl) acetamid-derivate als p2x7-antagonisten zur behandlung von schmerzen, entzündungen und neurodegeneration
CY1117696T1 (el) ΝΕΑ ΠΑΡΑΓΩΓΑ ΚΥΚΛΟΕΞΥΛΑΜΙΝΗΣ ΜΕ ΔΡΑΣΕΙΣ β2 ΑΔΡΕΝΕΡΓΙΚΟΥ ΑΓΩΝΙΣΤΗ ΚΑΙ Μ3 ΜΟΥΣΚΑΡΙΝΙΚΟΥ ΑΝΤΑΓΩΝΙΣΤΗ
ATE482209T1 (de) Verbindungen und zusammensetzungen als modulatoren der gpr119-aktivität
BRPI0908276B8 (pt) uso de um anticorpo antagonista anti-cgrp para a fabricação de um medicamento para a prevenção e/ou tratamento de dor de osteoartrite
EA201270184A1 (ru) Лечение расстройств печени ингибиторами pi3k
CY1114492T1 (el) Συνδυασμος αλφα 7 νικοτινικων αγωνιστων και αντιψυχωσικων
MX2010002732A (es) Inhibidores de f1f0-atpasa y metodos relacionados.
UA112514C2 (uk) АНТАГОНІСТИ C5aR
EA200870425A1 (ru) Применение агонистов рецептора grp119 для повышения костной массы и для лечения остеопороза и связанной с ними комбинированной терапии
MA32934B1 (fr) Combinaisons inhibitrices hsp90
CY1111927T1 (el) Νεες ενωσεις ως διαμορφωτες υποδοχεα οπιοειδων
CY1118007T1 (el) Μεθοδοι για την χορηγηση υπογλυκαιμικων μεσων
CY1111896T1 (el) Απαραβιαστες φαρμακευτικες μορφες δοσολογιας δια του στοματος περιλαμβανουσες ενα οπιουχο αναλγητικο
CY1111296T1 (el) Ενωσεις υποκατεστημενου ινδολιου που εχουν ανασταλτικη δραστικοτητα nos
NO20074943L (no) Roflumilast for behandlingen av diabetes mellitus
SV2009003212A (es) Inhibidores de metaloproteasa derivados de heterociclicos ref. prd2727svpct
MX354402B (es) Inhibidores de molecula pequeña del dominio de homologia de pleckstrin y metodos para usar los mismos.
NO20083011L (no) Modulatorer av muskarine receptorer
EA200901339A1 (ru) Ороназофарингеально доставляемая фармацевтическая композиция агонистов дофамина для предупреждения/облегчения и/или лечения расстройств беспокойных конечностей